ALV-100
Novel recombinant humanized GIPR antagonist IgG-4 antibody and GLP-1 receptor agonist peptide fusion protein.
GLP-1R agonism, a well-validated mechanism with strong clinical support, suppresses appetite and drives weight loss. GIPR antagonism, supported by human genetics, enhances the weight-loss effects of GLP-1R agonism, and via an ALV-100's extended-half-life antibody, enables less frequent dosing. ALV-100 showed competitive in vitro potency, weight loss, and lean mass preservation in obese non-human primates. Weight loss and weight maintenance were also demonstrated in a Phase 1 clinical trial.
ALV-200
ALV-200 is a subcutaneously administered peptide agonist of the AMYR3 receptor, engineered for high selectivity over the calcitonin receptor alone.
Precision by design sits at the core of the programme. Rather than combining amylin and calcitonin receptor activity, ALV-200 has been engineered to focus its pharmacology on amylin receptor signalling. Our aim in taking this approach is to harness the metabolic effects of amylin while minimising calcitonin receptor engagement: a design intended to support both metabolic benefit and tolerability. ALV-200 is an investigational agent in nonclinical development.
ALV-300
Most amylin analogues in clinical development are injectable peptides with dual amylin–calcitonin receptor activity (DACRAs).
ALV-300 is an orally administered small molecule with a strong preclinical profile designed to engage the same dual amylin–calcitonin receptor pharmacology. Our aim in pursuing an oral small molecule is to broaden access to amylin-based therapy.
ALV-300 is an investigational agent in nonclinical development.
Why it matters
The scientific rationale behind our programs is grounded in human genetics and biology: targeting mechanisms that are known to impact human weight loss, weight regain, and metabolism.
ALV-100 is now enrolling for the Phase 1b weight loss study. Learn more about participation and eligibility.